Current and Emerging Therapies for Rheumatoid Arthritis
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".
Deadline for manuscript submissions: 10 July 2025 | Viewed by 48
Special Issue Editor
Interests: rheumatoid arthritis; sjögren's syndrome; autoimmune diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The introduction of disease-modifying anti rheumatic drugs (DMARDs) has enabled rheumatologists to rescue patients with rheumatoid arthritis (RA) from joint destruction. Therapy of RA with DMARDs is still evolving, along with clinical applications of molecular targeted therapies: newly introduced biological DMARDs and targeted synthetic DMARDs, i.e., JAK inhibitors. Considering the present situation in the rheumatology department, we planned this Special Issue, titled ‘Current and Emerging Therapies for Rheumatoid Arthritis’, the aim of which is to disseminate up-to-date knowledge on current and emerging therapies for RA worldwide. We welcome authors to submit interesting papers, either original research or review, on the current topics regarding the advances in RA therapy.
Dr. Yoshiro Horai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DMARDs (disease-modifying anti-rheumatic drugs)
- boDMARDs (biological DMARDs)
- bsDMARDs (biosimilar DMARDs)
- csDMARDs (conventional synthetic DMARDs)
- rheumatoid arthritis
- tsDMARDs (targeted synthetic DMARDs)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
